Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

Completed · Phase 4 · Has a placebo group

Conditions studied: Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Healthy

In brief

This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory learning.

Key facts

Study ID

NCT03860597

Run by

University of California, San Diego

People needed

42

Starts

2018-04-01

Expected to finish

2021-03-31

Last updated by the study team

2022-12-21

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• diagnosis of schizophrenia OR schizoaffective-depressed OR healthy subjects
• ages 18-50 for all subjects
• double barrier contraception for all subjects
• not pregnant for all subjects

You may not qualify if…

• DSM-IV Axis I or II Diagnosis for for healthy subjects
• MEM or amantadine for patients
• current substance abuse for all subjects
• current recreational drug use for all subjects
• history of other significant medical illness (e.g. cancer, diabetes, heart disease, HIV, seizures) for all subjects
• open head injury or closed head injury with loss of consciousness > 1 min for all subjects
• hearing or visual impairment for all subjects
• pregnancy for all subjects
• dementia for all subjects
• mental retardation for all subjects

Where it is running

• Clinical Teaching Facility (CTF-B102) at UCSD Medical Center — San Diego, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.